Total Valuation
GenSight Biologics SA has a market cap or net worth of €26.70M. The enterprise value is €29.15.
Market Cap€26.70M
Enterprise Value€29.15
Share Statistics
GenSight Biologics SA has 235,044,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding235,044,330
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
GenSight Biologics SA’s return on equity (ROE) is 0.48 and return on invested capital (ROIC) is 1518.16%.
Return on Equity (ROE)0.48
Return on Assets (ROA)-1.46
Return on Invested Capital (ROIC)1518.16%
Return on Capital Employed (ROCE)2.65
Revenue Per Employee76.92
Profits Per Employee-925.85K
Employee Count13
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of GenSight Biologics SA is ―. GenSight Biologics SA’s PEG ratio is 0.03.
PE Ratio―
PS Ratio15482.52
PB Ratio-0.62
Price to Fair Value-0.62
Price to FCF-1.65
Price to Operating Cash Flow-2.70
PEG Ratio0.03
Income Statement
In the last 12 months, GenSight Biologics SA had revenue of 1.00K and earned -12.04M in profits. Earnings per share was -0.08.
Revenue1.00K
Gross Profit1.00K
Operating Income-11.71M
Pretax Income-12.04M
Net Income-12.04M
EBITDA-11.24M
Earnings Per Share (EPS)-0.08
Cash Flow
In the last 12 months, operating cash flow was -8.22M and capital expenditures 6.43M, giving a free cash flow of -8.50M billion.
Operating Cash Flow-8.22M
Free Cash Flow-8.50M
Free Cash Flow per Share-0.04
Dividends & Yields
GenSight Biologics SA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.96
52-Week Price Change-36.94%
50-Day Moving Average0.09
200-Day Moving Average0.08
Relative Strength Index (RSI)48.64
Average Volume (3m)0.00
Important Dates
GenSight Biologics SA upcoming earnings date is Mar 19, 2027, TBA (Confirmed).
Last Earnings DateSep 29, 2026
Next Earnings DateMar 19, 2027
Ex-Dividend Date―
Financial Position
GenSight Biologics SA as a current ratio of 0.39, with Debt / Equity ratio of -38.18%
Current Ratio0.39
Quick Ratio0.39
Debt to Market Cap0.81
Net Debt to EBITDA-0.93
Interest Coverage Ratio-11.86
Taxes
In the past 12 months, GenSight Biologics SA has paid 5.00K in taxes.
Income Tax5.00K
Effective Tax Rate>-0.01
Enterprise Valuation
GenSight Biologics SA EV to EBITDA ratio is -2.31, with an EV/FCF ratio of -2.76.
EV to Sales25.93K
EV to EBITDA-2.31
EV to Free Cash Flow-2.76
EV to Operating Cash Flow-2.77
Balance Sheet
GenSight Biologics SA has €1.67M in cash and marketable securities with €12.84M in debt, giving a net cash position of -€11.16M billion.
Cash & Marketable Securities€1.67M
Total Debt€12.84M
Net Cash-€11.16M
Net Cash Per Share-€0.05
Tangible Book Value Per Share-€0.17
Margins
Gross margin is 3.74%, with operating margin of -1170500.00%, and net profit margin of -1203600.00%.
Gross Margin3.74%
Operating Margin-1170500.00%
Pretax Margin-1204100.00%
Net Profit Margin-1203600.00%
EBITDA Margin-1124000.00%
EBIT Margin-1170500.00%
Analyst Forecast
The average price target for GenSight Biologics SA is €0.08, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target€0.08
Price Target Upside33.33% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-610.31%
EPS Growth Forecast43.88%